PMID

Data

Article Title

Organization

Shape-based reprofiling of FDA-approved drugs for the H1 histamine receptor.

University Of Oxford

From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.

The Johns Hopkins University School Of Medicine

Novel piperazines: potent melanocortin-4 receptor antagonists with anxiolytic-like activity.

Taisho Pharmaceutical

Pyrrolo[1,3]benzothiazepine-based atypical antipsychotic agents. Synthesis, structure-activity relationship, molecular modeling, and biological studies.

Universit£

N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.

Eli Lilly

Development of predictive retention-activity relationship models of tricyclic antidepressants by micellar liquid chromatography.

Universidad De Valencia

New benzocycloalkylpiperazines, potent and selective 5-HT1A receptor ligands.

Cooperation Pharmaceutique Fran�Aise

Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.

TBA

Pyrrolo[1,3]benzothiazepine-based serotonin and dopamine receptor antagonists. Molecular modeling, further structure-activity relationship studies, and identification of novel atypical antipsychotic agents.

Universit£

Ligand based design of novel histamine H4 receptor antagonists; fragment optimization and analysis of binding kinetics.

Griffin Discoveries

Novel spirotetracyclic zwitterionic dual H(1)/5-HT(2A) receptor antagonists for the treatment of sleep disorders.

Glaxosmithkline

 

Dual antagonists of platelet activating factor and histamine. 2. pyridine ring substitution of N-acetyl-4-(8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)piperidines

TBA

Novel sigma receptor ligands: synthesis and biological profile.

University Of Catania

Structure-activity relationships of novel piperazines as antagonists for the melanocortin-4 receptor.

Taisho Pharmaceutical

Identification of a 5-HT4 receptor antagonist clinical candidate through side-chain modification.

Roche Palo Alto

Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine.

The Schering Plough Research Institute

Synthesis and pharmacological evaluation of 6-piperidino- and 6-piperazinoalkyl-2(3H)-benzothiazolones as mixed sigma/5-HT(1A) ligands.

Université

N-Substituted (2,3-dihydro-1,4-benzodioxin-2-yl)methylamine derivatives as D(2) antagonists/5-HT(1A) partial agonists with potential as atypical antipsychotic agents.

Knoll Pharmaceuticals

New (sulfonyloxy)piperazinyldibenzazepines as potential atypical antipsychotics: chemistry and pharmacological evaluation.

University Of GöTeborg

Dual antagonists of platelet activating factor and histamine. 3. Synthesis, biological activity and conformational implications of substituted N-acyl-bis-arylcycloheptapiperazines.

Schering-Plough Research Institute

Synthesis and pharmacological evaluation of triflate-substituted analogues of clozapine: identification of a novel atypical neuroleptic.

University Of Groningen

Dopamine D3 and D4 receptor antagonists: synthesis and structure--activity relationships of (S)-(+)-N-(1-Benzyl-3-pyrrolidinyl)-5-chloro-4- [(cyclopropylcarbonyl) amino]-2-methoxybenzamide (YM-43611) and related compounds.

Yamanouchi Pharmaceutical

Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.

Solvay Duphar

In vitro labeling of serotonin-S2 receptors: synthesis and binding characteristics of [3H]-7-aminoketanserin.

TBA

Dual antagonists of platelet activating factor and histamine. Identification of structural requirements for dual activity of N-Acyl-4-(5,6-dihydro-11H-benzo [5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines.

Schering-Plough

Small Molecule Inhibitors of 8-Oxoguanine DNA Glycosylase-1 (OGG1).

Oregon Health & Science University

Structure and Inhibition of Microbiome ß-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity.

University Of North Carolina At Chapel Hill